



US008497277B2

(12) **United States Patent**
Honigberg et al.

(10) **Patent No.:** **US 8,497,277 B2**
(45) **Date of Patent:** ***Jul. 30, 2013**

(54) **INHIBITORS OF BRUTON'S TYROSINE KINASE**
(75) Inventors: **Lee Honigberg**, San Francisco, CA (US); **Erik Verner**, Belmont, CA (US); **Zhengying Pan**, Austin, TX (US)

(73) Assignee: **Pharmacyclics, Inc.**, Sunnyvale, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/312,606**

(22) Filed: **Dec. 6, 2011**

(65) **Prior Publication Data**

US 2012/0095026 A1 Apr. 19, 2012

Related U.S. Application Data

(60) Continuation of application No. 13/249,066, filed on Sep. 29, 2011, which is a continuation of application No. 12/356,498, filed on Jan. 20, 2009, now Pat. No. 8,088,781, which is a division of application No. 11/617,645, filed on Dec. 28, 2006, now Pat. No. 7,514,444.

(60) Provisional application No. 60/826,720, filed on Sep. 22, 2006, provisional application No. 60/828,590, filed on Oct. 6, 2006.

(51) **Int. Cl.**
A01N 43/90 (2006.01)
A61K 31/519 (2006.01)
C07D 487/00 (2006.01)

(52) **U.S. Cl.**
USPC **514/262.1; 544/262**

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,397,787 A 3/1995 Buzzetti
6,160,010 A 12/2000 Uckun et al.
6,221,900 B1 4/2001 Uckun et al.
6,326,469 B1 12/2001 Ullrich et al.
6,506,769 B2 1/2003 Snow et al.
6,660,744 B1 12/2003 Hirst et al.
6,753,348 B2 6/2004 Uckun et al.
6,770,639 B2 8/2004 Snow et al.
6,921,763 B2 7/2005 Hirst et al.
7,138,420 B2 11/2006 Bentzien et al.
7,332,497 B2 2/2008 Hirst et al.
7,514,444 B2 4/2009 Honigberg et al.
7,718,662 B1 5/2010 Chen
7,732,454 B2 6/2010 Verner
7,741,330 B1 6/2010 Chen

8,008,309 B2 8/2011 Honigberg et al.
8,088,781 B2 1/2012 Honigberg et al.
8,158,786 B2 4/2012 Honigberg et al.
8,232,280 B2 7/2012 Honigberg et al.
8,236,812 B2 8/2012 Honigberg et al.
2002/0016460 A1 2/2002 Snow et al.
2002/0155505 A1 10/2002 Wells et al.
2003/0013125 A1 1/2003 Braisted et al.
2003/0040461 A1 2/2003 Mcatee
2003/0125235 A1 7/2003 Foxwell
2004/0006083 A1 1/2004 Hirst et al.
2005/0008640 A1 1/2005 Waegell et al.
2005/0084905 A1 4/2005 Prescott et al.
2005/0090499 A1 4/2005 Currie et al.
2005/0101604 A1 5/2005 Currie et al.
2005/0196851 A1 9/2005 Uckun
2005/0209255 A1 9/2005 Jimenez et al.
2006/0079494 A1 4/2006 Santi et al.
2006/0167090 A1 7/2006 Uckun et al.
2007/0281907 A1 12/2007 Watkins
2008/0076921 A1 3/2008 Honigberg et al.
2008/0108636 A1 5/2008 Honigberg et al.
2008/0214501 A1 9/2008 Pan
2009/0105209 A1 4/2009 Dewdney et al.
2009/0181987 A1 7/2009 Honigberg
2010/0004270 A1 1/2010 Honigberg
2010/0022561 A1 1/2010 Honigberg et al.
2010/0041677 A1 2/2010 Honigberg et al.
2010/0254905 A1 10/2010 Honigberg et al.
2010/0324050 A1 12/2010 Honigberg et al.
2011/0039868 A1 2/2011 Honigberg et al.

(Continued)

FOREIGN PATENT DOCUMENTS

EP 1473039 11/2004
WO WO-97-28161 8/1997

(Continued)

OTHER PUBLICATIONS

Apfel et al. "Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases." *Nature Chem. Bio.* 2008, 4(11):691-699.
Arnold, L.D. et al., "Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of Ick 1," *Bioorg. Med. Chem. Ltrs.* 10:2167-2170 (2000).
Browning, J.L., "B cells move to centre stage: novel opportunities for autoimmune disease treatment", *Nature Reviews/Drug Discovery* vol. 5, Jul. 2006, pp. 564-576.

(Continued)

Primary Examiner — Jeffrey Murray

(74) *Attorney, Agent, or Firm* — Wilson, Sonsini, Goodrich & Rosati

(57) **ABSTRACT**

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

U.S. PATENT DOCUMENTS

2011/0086866	A1	4/2011	Chen
2011/0177011	A1	7/2011	Currie et al.
2011/0224235	A1	9/2011	Honigberg et al.
2011/0281322	A1	11/2011	Honigberg et al.
2012/0065201	A1	3/2012	Honigberg et al.
2012/0071497	A1	3/2012	Buggy et al.
2012/0087915	A1	4/2012	Buggy et al.
2012/0088912	A1	4/2012	Honigberg et al.
2012/0095026	A1	4/2012	Honigberg et al.
2012/0100138	A1	4/2012	Buggy et al.
2012/0101113	A1	4/2012	Honigberg et al.
2012/0101114	A1	4/2012	Honigberg et al.
2012/0108612	A1	5/2012	Honigberg et al.
2012/0115889	A1	5/2012	Honigberg et al.
2012/0122894	A1	5/2012	Honigberg et al.
2012/0129821	A1	5/2012	Honigberg et al.
2012/0129873	A1	5/2012	Honigberg et al.
2012/0135944	A1	5/2012	Honigberg et al.
2012/0165328	A1	6/2012	Honigberg et al.
2012/0178753	A1	7/2012	Honigberg et al.
2012/0183535	A1	7/2012	Buggy et al.
2012/0184013	A1	7/2012	Honigberg et al.
2012/0184567	A1	7/2012	Honigberg et al.
2012/0202264	A1	8/2012	Honigberg et al.
2012/0214826	A1	8/2012	Honigberg et al.
2012/0252821	A1	10/2012	Honigberg et al.
2012/0252822	A1	10/2012	Honigberg et al.
2012/0277225	A1	11/2012	Honigberg et al.
2012/0277254	A1	11/2012	Honigberg et al.
2012/0277255	A1	11/2012	Honigberg et al.
2012/0283276	A1	11/2012	Honigberg et al.
2012/0283277	A1	11/2012	Honigberg et al.
2012/0296089	A1	11/2012	Honigberg et al.
2012/0329130	A1	12/2012	Honigberg et al.
2013/0005745	A1	1/2013	Honigberg et al.
2013/0005746	A1	1/2013	Honigberg et al.
2013/0012525	A1	1/2013	Honigberg et al.
2013/0018060	A1	1/2013	Honigberg et al.
2013/0035334	A1	2/2013	Honigberg et al.

FOREIGN PATENT DOCUMENTS

WO	WO-99-54286	10/1999
WO	WO-00-00823	1/2000
WO	WO-00-56737	A2 9/2000
WO	WO-01-19829	A2 3/2001
WO	WO-01-19829	A3 3/2001
WO	WO-01-25238	A2 4/2001
WO	WO-01-41754	6/2001
WO	WO-01-44258	A1 6/2001
WO	WO-0141754	6/2001
WO	WO-02-38797	A2 5/2002
WO	WO-02-076986	A1 10/2002
WO	WO-02-080926	10/2002
WO	WO-03-000187	1/2003
WO	WO-03-013540	2/2003
WO	WO-03-046200	6/2003
WO	WO-03-097645	11/2003
WO	WO-2004-074290	9/2004
WO	WO-2004-096253	11/2004
WO	WO-2004-100868	A2 11/2004
WO	WO 2004-100868	A2 11/2004
WO	WO-2004-100868	A3 11/2004
WO	WO-2005-000197	1/2005
WO	WO-2005-005429	1/2005
WO	WO-2005-014599	2/2005
WO	WO-2005-037843	4/2005
WO	WO-2005-060956	7/2005
WO	WO-2005-074603	8/2005
WO	WO-2006-036527	4/2006
WO	WO-2006-050946	5/2006
WO	WO-2006-053121	5/2006
WO	WO-2006-099075	9/2006
WO	WO-2006-124462	11/2006
WO	WO-2007-002325	1/2007
WO	WO-2007-058832	5/2007

WO	WO-2008-039218	4/2008
WO	WO-2008-054827	A2 5/2008
WO	WO-2008-121742	10/2008
WO	WO-2009-051822	4/2009
WO	WO-2009-158571	12/2009
WO	WO-2010-009342	A2 1/2010
WO	WO-2010-009342	A3 1/2010
WO	WO-2010-126960	11/2010
WO	WO-2011-034907	3/2011
WO	WO-2011-153514	12/2011
WO	WO-2011-162515	12/2011
WO	WO-2012-021444	2/2012

OTHER PUBLICATIONS

Chang et al. "The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells." *Arthritis Research & Therapy* 2011, 13:R115.

Cohen, M.S. et al., "Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors," *Science*, vol. 308, May 27, 2005, pp. 1318-1321.

Desiderio, S., "Role of Btk in B cell development and signaling," *Curr. Op. in Immunology* 1997, 9:534-540.

Dorwald, F. A. *Side Reactions in Organic Synthesis*, Wiley:VCH, Weinheim p. IX. of Preface, Wiley-VCH Verlag GmbH & Co. KGaA (2005).

Fruman, D.A., "Xid-like Phenotypes: A B Cell Signalosome Takes Shape," *Immunity* 13:1-3 (Jul. 2000).

Gold, Michael R., "To make antibodies or not: signaling by the B-cell antigen receptor," *Trends in Pharmacological Sciences*, 23(7):316-324 (Jul. 2002).

Horwood, Nicole J. et al., "Bruton's Tyrosin Kinase is Required for Lipopolysaccharide—induced Tumor Necrosis Factor α Production," *J. Exp. Med.* 197(12):1603-1611 (Jun. 2003).

Iwaki, Shoki et al., "Btk Plays a Crucial Role in the Amplification of Fc ϵ RI-mediated Mast Cell Activation by Kit," *J. Biol. Chem.* 280(48):40261-40270 (Dec. 2, 2005).

Jefferies, Caroline A. et al., "Bruton's Tyrosine Kinase is a Toll/Interleukin-1 Receptor Domain-binding Protein That Participates in Nuclear Factor κ B Activation by Toll-like Receptor 4," *J. Biol. Chem.* 278:26258-26264 (2003).

Kawakami, Yuko et al., "Terreic acid, a quinone epoxide inhibitor of Bruton's tyrosine kinase," *PNAS USA* 96:2227-2232 (1999).

Kuppers, R., "Mechanisms of B-cell lymphoma pathogenesis," *Nature Reviews/Cancer*, vol. 5, Apr. 2005, pp. 251-262.

Kurosaki, Tomohiro, "Functional dissection of BCR signaling pathways," *Curr. Op. Imm.* 12:276-281 (2000).

Lui, Yi et al. "Structural Basis for selective inhibition of Src family kinases by PPI." *Chemistry and Biology*, 1999, No. 6, pp. 671-678, in particular table 1, p. 671.

Mahajan, S. et al., "Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting Bruton's Tyrosine Kinase (BTK), LFM-A13 [α -Cyano- β -Methyl-N-(2,5-Dibromophenyl)Propenamide]," *J. of Biol. Chem.*, vol. 274, No. 14, Apr. 2, 1999, pp. 9587-9599.

Mangla, Anita et al., "Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses," *Blood* 104(4):1191-1197 (2004).

Niuro, Hiroaki and Clark, Edward A., "Regulation of B-Cell Fate by Antigen-Receptor Signals," *Nature Reviews* 2:945-956 (2002).

Nisitani, S. et al., "In situ detection of activated Bruton's tyrosine kinase in the Ig signaling complex by phosphopeptide-specific monoclonal antibodies," *PNAS USA* 96:2221-2226 (1999).

Oligino, Thomas J. and Dalrymple, Stacie A., "Targeting B cells for the treatment of rheumatoid arthritis," *Arthritis Res Ther* 5(Suppl. 4):S7-S11 (2002).

Pan, Z. et al., "Discovery of Selectable Irreversible Inhibitors for Bruton's Tyrosine Kinase," *ChemMedChem* 2006, 1, 1-5.

Pan, Zhengying et al., "Discovery of Selective Irreversible Inhibitors for Bruton's Tyrosine Kinase," *ChemMedChem* 2007, 2:58-61, compound 1 et al, table 1.

- Sada, Kiyonao and Yamamura, Hirohei, "Protein-Tyrosine Kinases and Adaptor Proteins in FceRI-Mediated Signaling in Mast Cells," *Curr. Mol. Med.* 3(1):85-94 (2003).
- Schaeffer, Edward M. and Schwartzberg, Pamela L., "Tec family kinases in lymphocyte signaling and function," *Curr. Op. Imm.* 12:282-288 (2000).
- Shaffer, A.L. et al., Lymphoid malignancies: the dark side of B-cell differentiation, *Nature Reviews/Immunology*, vol. 2, Dec. 2002, pp. 920-932.
- Smaill, J.B. et al., "Tyrosine Kinase Inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(Phenylamino)prido[d]pyrimidine Acrylamides as Irreversible Inhibitors of the ATP Binding Site of the Epidermal Growth Factor Receptor," *J. Med. Chem.* 42(10):1803-1815 (1999).
- Smith, C.I. Edvard et al., "The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species," *BioEssays* 23:436446 (2001).
- Smolen, Josef S. and Steiner, Gunter, "Therapeutic Strategies for Rheumatoid Arthritis," *Nature Reviews* 2:473-488 (2003).
- Traxler et al. "Use of a Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors: 4-(Phenylamino)pyrazolo[3,4-d]pyrimidines." *J. Med Chem* 1997, 40(22):3601-3616.
- Uckun, Fatih M. et al., "The Anti-leukemic Bruton's Tyrosin Kinase Inhibitor α -cyano- β -hydroxy- β -methyl-N-(2,5-dibromophenyl)Propenamide (LFM-A13) Prevents Fatal Thromboembolism," *Leuk. Lymphoma* 44(9):1569-1577 (2003).
- Uckun, Fatih M. et al., "In Vivo Pharmacokinetic Features, Toxicity Profile, and Chemosensitizing Activity of α -Cyano- β -hydroxy- β -methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a Novel Antileukemic Agent Targeting Bruton's Tyrosine Kinase," *Clin. Cancer Res.* 8:1224-1233 (2002).
- Uckun, F.M., "Bruton's Tyrosin Kinase (BTK) as a Dual-Function Regulator of Apoptosis," *Biochem. Pharmacology*, vol. 56, pp. 683-691, 1998.
- Uckun, Fatih M. et al., "BTK as a Mediator of Radiation-Induced Apoptosis in DT-40 Lymphoma B Cells," *Science* vol. 273 No. 5278, pp. 1096-1100 (1996).
- Ucken et al. "Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity," *Expert Opinion Ther. Patents* 2010, 20(11):1-14.
- Vassilev, A.O. and Uckun, F.M., "Therapeutic Potential of Inhibiting Bruton's Tyrosine Kinase, (BTK)," *Current Pharmaceutical Design*, 2004, 10, 1757-1766.
- Vassilev, Alexei et al., "Bruton's Tyrosine Kinase as an Inhibitor of the Fas/CD95 Death-inducing Signaling Complex," *J. Biol. Chem.* 274(3):1646-1656 (1999).
- Vippagunta et al., "Crystalline Solids," *Advanced Drug Delivery Reviews* 48:3-26 (2001).
- Yamamoto, Noriyuki et al., "The Orally Available Spleen Tyrosine Kinase Inhibitor 247-(3,4-Dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]-nicotinamide Dihydrochloride (BAY61-3606) Blocks Antigen-Induced Airway Inflammation in Rodents," *J. Pharma. and Exp. Therapeutics* 306(3):1174-1181 (2003).
- EP06850039 Supplemental Search Report dated Feb. 9, 2010.
- EP06850386.1 Search Report and Written Opinion dated Sep. 10, 2010.
- <http://www.uspto.gov/web/offices/pac/dapp/lpecba.htm#7>, last accessed Feb. 16, 2011.
- U.S. Appl. No. 13/011,258 mailed Nov. 22, 2011.
- EP 10155834.4 Search Report dated May 19, 2010.
- EP08744513 Supplementary Search Report dated Mar. 11, 2010.
- EP10823966 Supplementary European Search Report mailed Oct. 17, 2011.
- U.S. Appl. No. 13/654,173, filed Oct. 17, 2012, Honigberg et al.
- U.S. Appl. No. 13/736,812, filed Jan. 8, 2013, Buggy et al.
- Advani et al. "The BTK inhibitor PCI-32765 is highly active and well tolerated in patients (PTS) with relapsed/refractory B cell malignancies: final results from a phase I study", *Ann. Oncol.*, 22(suppl 4): abstract 153 (2011).
- Banker et al. "Modern Pharmaceuticals," p. 596 (1996).
- Brown et al. "Phase Ib trial of AVL-292, a covalent inhibitor of 30(suppl):abstract 8032 (2012); [online][retrieved on Oct. 4, 2012] Retrieved from the Internet: <http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=98841>.
- Burger, J.A., "Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape", *Curr. Opin. Oncol.* (Epub Sep 6, 2012), 24(6):643-649 (Nov. 2012).
- Carmi et al. "Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer," *Biochem. Pharmacol.* (Epub Aug. 4, 2012), 84(11):1388-1399 (Dec. 2012).
- Czuczman et al. "Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma", *J. Clin. Oncol.* 23(4):694-704 (Feb. 1, 2005).
- Dauids et al. "Targeting the B Cell Receptor Pathway in Chronic Lymphocytic Leukemia", *Leuk. Lymphoma* (Epub May 23, 2012), 53(12):2362-2370 (Dec. 2012).
- EA200901313 Notification of Office Action mailed Oct. 31, 2011.
- Edwards, C.M., "BTK inhibition in myeloma: targeting the seed and the soil", *Blood* 120(9):1757-1759 (Aug. 2012).
- EP 06850039.6 Search Report and Written Opinion dated Feb. 15, 2010.
- EP 08744513.6 Search Report and Written Opinion dated Mar. 18, 2010.
- EP 09798770.5 Search Report and Written Opinion dated Oct. 28, 2011.
- EP 10155834.4 Search Report and Written Opinion dated May 27, 2010.
- EP 10823966.6 Written Opinion dated Dec. 6, 2011.
- EP 12151943.3 Search Report and Written Opinion dated Mar. 13, 2012.
- EP 12166295.1 Search Report and Written Opinion dated Nov. 6, 2012.
- EP 12166296.9 Search Report and Written Opinion dated Nov. 8, 2012.
- EP 12166298.5 Search Report and Written Opinion dated Nov. 7, 2012.
- EP 12166300.9 Search Report and Written Opinion dated Oct. 31, 2012.
- EP 12166301.7 Search Report and Written Opinion dated Nov. 6, 2012.
- EP 12166302.5 Search Report and Written Opinion dated Nov. 6, 2012.
- EP 12166305.8 Search Report and Written Opinion dated Nov. 6, 2012.
- EP 12166306.6 Search Report and Written Opinion dated Nov. 8, 2012.
- EP 12172840.6 Search Report and Written Opinion dated Dec. 12, 2012.
- EP 12172841.4 Search Report and Written Opinion dated Jan. 2, 2013.
- Fisher et al. "Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse", *Ann. Intern. Med.*, 90(5):761-763 (1979).
- Fowler et al. "The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma", 54th American Society of Hematology Annual Meeting and Exposition, Atlanta, GA, Abstract 156 (Dec. 8-11, 2012).
- Giuliani, N., "Multiple myeloma bone disease: pathophysiology of osteoblast inhibition," *Blood* (Epub Aug. 17, 2006), 108(13):3992-3996 (2006).
- Hantschel et al. "The Btk Tyrosine Kinase is a Major Target of the Bcr-Abl Inhibitor Dasatinib", *PNAS* 104(33):13283-13288 (2007).
- Hata et al. "Bruton's tyrosine kinase-mediated Interleukin-2 gene activation in mast cells," *J. Biol. Chem.* 273(18): 10979-10987 (1998).
- Herman et al. "Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is

- Hiddeman et al. "Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group", *Blood* (Epub Aug. 25, 2005), 106(12):3725-3732 (Dec. 2005).
- Korade-Mjrnics et al. "Src kinase-mediated signaling in leukocytes," *J. Leukoc. Bio.*, 68(5):603-613 (Nov. 2000).
- Kozaki et al. "Development of a Bruton's tyrosine kinase (Btk) inhibitor -ONO-WG-307, a potential treatment for B-cell malignancies", 53rd American Society of Hematology Annual Meeting and Exposition, San Diego, CA, Poster #857 (Dec. 10-13, 2011).
- Mallis et al. "Structural characterization of a proline-driven conformational switch within the Itk SH2 domain," *Nat. Struct. Biol.*, 9(12):900-905 (2002).
- Middendorp et al. "Tumor Suppressor Function of Bruton Tyrosine Kinase is Independent of its catalytic activity", *Blood* 105(0):259-261 (2005).
- Mukoyama et al., "Preparation of imidazol [1,5-a]pyrazine derivatives, pharmaceutical compositions containing them, and their uses for prevention or treatment of protein tyrosine kinase-related diseases," retrieved from STN Database Accession No. 2005:299462, Patent No. JP2005089352, Apr. 7, 2005, *abstract*.
- Pagel et al. "Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas", *Clin. Cancer Res.* (Epub Jul. 6, 2005), 11(13):4857-4866 (2005).
- PCT/US09/50897 IPER and Written Opinion dated Jan. 27, 2011.
- PCT/US09/50897 Search Report dated Mar. 15, 2010.
- Peterson et al. "Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group", *Br. J. Clin. Oncol.*, 21(1):5-15 (Jan. 1, 2003).
- Ponader et al. "The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo", *Blood* (Epub Dec. 16, 2011), 119(5):1182-1189 (Feb. 2012).
- Powers et al. "Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases," *Chem. Rev.*, 102(12):4639-4750 (2002).
- Prakash et al. "Chicken sarcoma to human cancers: a lesson in molecular therapeutics," *The Ochsner Journal*, 7(2):61-64 (Jan. 1, 2007).
- Robak et al. "A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia", *Curr. Med. Chem.* (Epub Jul. 24, 2012), 19(31):5294-5318 (2012).
- Robak et al. "Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders", *Expert Opin. Investig. Drugs* (Epub May 22, 2012), 21(7):921-947 (Jul. 2012).
- Rushworth et al. "BTK inhibitor ibrutinib is cytotoxic to myeloma and potentially enhances bortezomib and lenalidomide activities through NF-κB", *Cell Signal* (Epub Sep. 11, 2012), 25(1):106-112 (Jan. 2013).
- Schwamb et al. "B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides", *Blood* (Epub Aug. 27, 2012), 120(19):3978-3985 (Nov. 2012).
- U.S. Appl. No. 11/617,645 Final Office Action mailed Oct. 16, 2008.
- U.S. Appl. No. 11/617,645 Notice of Allowance mailed Feb. 9, 2009.
- U.S. Appl. No. 11/617,645 Office Action mailed Jan. 24, 2008.
- U.S. Appl. No. 11/617,645 Office Action mailed May 13, 2008.
- U.S. Appl. No. 11/692,870 Final Office Action mailed Aug. 19, 2009.
- U.S. Appl. No. 11/692,870 Office Action mailed Jan. 26, 2009.
- U.S. Appl. No. 12/356,498 Final Office Action mailed Jul. 8, 2011.
- U.S. Appl. No. 12/356,498 Office Action mailed Apr. 14, 2011.
- U.S. Appl. No. 12/499,002 Final Office Action mailed Dec. 14, 2012.
- U.S. Appl. No. 12/499,002 Final Office Action mailed Oct. 25, 2011.
- U.S. Appl. No. 12/499,002 Office Action mailed Jun. 5, 2012.
- U.S. Appl. No. 12/499,008 Office Action mailed Jul. 19, 2011.
- U.S. Appl. No. 12/594,805 Office Action mailed Oct. 15, 2012.
- U.S. Serial No. 12/727,703 Final Office Action mailed Jul. 19, 2011.
- U.S. Appl. No. 12/887,428 Office Action mailed Apr. 20, 2011.
- U.S. Appl. No. 13/312,606 Office Action mailed Sep. 19, 2012.
- U.S. Appl. No. 13/328,718 Final Office Action mailed Dec. 27, 2012.
- U.S. Appl. No. 13/328,718 Office Action mailed Jul. 3, 2012.
- U.S. Appl. No. 13/340,276 Office Action mailed Sep. 26, 2012.
- U.S. Appl. No. 13/361,733 Notice of Allowance mailed Nov. 14, 2012.
- U.S. Appl. No. 13/361,733 Office Action mailed Jul. 6, 2012.
- U.S. Appl. No. 13/404,422 Office Action mailed Sep. 28, 2012.
- U.S. Appl. No. 13/410,110 Office Action mailed Sep. 28, 2012.
- U.S. Appl. No. 13/439,775 Office Action mailed Dec. 10, 2012.
- U.S. Appl. No. 13/526,161 Office Action mailed Nov. 27, 2012.
- U.S. Appl. No. 13/526,163 Office Action mailed Nov. 28, 2012.
- U.S. Appl. No. 13/607,036 Office Action mailed Nov. 14, 2012.
- Vose, J.M., "Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management", *Am. J. Hematol.* 87(6):604-609 (Jun. 2012).
- Wilkinson et al. "Selective tyrosine kinase inhibitors," *Expert Opin. Emerging Drugs* 5(3):287-297 (2000).
- Witzens-Harig et al. "Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting", *Ann Hematol.* (Epub Aug. 29, 2012), 91(11):1765-1772 (Nov. 2012).
- Witzig et al. "Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma", *J. Clin. Oncol.* (Epub Oct. 5, 2009), 27:5404-5409 (2009).
- Wolff, M.E., "Burger's Medicinal Chemistry and Drug Discovery," 5th Ed. Part 1, pp. 975-977 (1995).
- Yasuhiro et al. "ONO-WG-307, a Novel, Potent and Selective Inhibitor of Bruton's Tyrosine Kinase, in sustained inhibition of the Erk, Akt and PKD signaling pathways", 53rd American Society of Hematology Annual Meeting and Exposition, San Diego, CA, Poster #2021 (Dec. 10-13, 2011).
- Zhu et al. "Calpain Inhibitor II Induces Caspase-dependent Apoptosis in Human Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma Cells as well as Some Solid Tumor Cells", *Clin. Cancer Res.* 6:2456-2463 (2000).
- EP 08744513.6 Examination Report dated Jan. 16, 2013.
- EP 12151943.3 Examination Report dated Feb. 5, 2013.
- EP 12172842.2 Partial Search Report dated Jan. 24, 2013.
- EP 12172843.0 Search Report and Written Opinion dated Jan. 18, 2013.
- U.S. Appl. No. 13/341,695 Office Action mailed Feb. 1, 2013.
- U.S. Appl. No. 13/747,322, filed Jan. 22, 2013, Buggy et al.
- U.S. Appl. No. 13/747,319, filed Jan. 22, 2013, Buggy et al.
- Tinmouth et al. "Fludarabine in alkylator-resistant follicular non-Hodgkin's lymphoma", *Leuk. Lymphoma*, 41(1-2):137-145 (2001).
- U.S. Appl. No. 13/340,409, filed Dec. 29, 2011, Honigberg et al.
- U.S. Appl. No. 13/606,949, filed Sep. 7, 2012, Honigberg et al.
- U.S. Appl. No. 13/612,143, filed Sep. 12, 2012, Honigberg et al.
- Advani et al. "The BTK inhibitor PCI-32765 is highly active and well tolerated in patients (PTS) with relapsed/refractory B cell malignancies: final results from a phase I study", *Ann. Oncol.*, 22(suppl 4): abstract 153 (2011).
- Apsel et al. "Targeted Polypharmacology: Discovery of Dual Inhibitors of Tyrosine and Phosphoinositide Kinases." *Nature Chem. Bio.*, 4(11):691-699 (2008).
- Arnold et al. "Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of Ick 1," *Bioorg. Med. Chem. Ltrs.* 10:2167-2170 (2000).
- Brown et al. "Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL)", *J. Clin. Oncol.* 30(suppl):abstract 8032 (2012); [online][retrieved on Oct. 4, 2012] Retrieved from the Internet: < http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=98841>.
- Browning, J.L., "B cells move to centre stage: novel opportunities for autoimmune disease treatment", *Nature Reviews/Drug Discovery*, 5:564-576 (Jul. 2006).
- Burchat et al., "Pyrazolo[3,4-d]pyrimidines Containing an Extended

- Carmi et al. "Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer," *Biochem. Pharmacol.* (Epub Aug 4, 2012), 84(11):1388-1399 (Dec. 2012).
- Chang et al. "The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells." *Arthritis Research & Therapy*, 13:R115 (2011).
- Cohen et al. "Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors," *Science*, 308:1318-1321 (May 27, 2005).
- Desiderio, S., "Role of Btk in B cell development and signaling," *Curr. Opin. Imm.* 9:534-540 (1997).
- Dorwald, F.Z., *Side Reactions in Organic Synthesis*, Wiley:VCH, Weinheim p. IX of Preface, Wiley-VCH Verlag GmbH & Co. KGaA (2005).
- EA201000599 Search Report dated Nov. 15, 2010.
- Edwards, C.M., "BTK inhibition in myeloma: targeting the seed and the soil", *Blood* 120(9):17574759 (Aug. 2012).
- EP 06850386.1 Search Report and Written Opinion dated Sep. 10, 2010.
- EP 08744513.6 Search Report and Written Opinion dated. Mar. 18, 2010.
- EP 10823966.6 Search Report dated Oct. 17, 2011.
- EP 1215943.3 Search Report and Written Opinion dated Mar. 13, 2012.
- EP 12166295.1 Search Report and Written Opinion dated. Nov. 6, 2012.
- Fabian et al. "A small molecule-kinase interaction map for clinical kinase inhibitors." *Nature Biotechnology*, 2005, 23(3): 329-336.
- Fruman, D.A., "Xid-like Phenotypes: A B Cell Signalosome Takes Shape", *Immunity*, 13:1-3 (Jul. 2000).
- Giuliani, N., "Multiple myeloma bone disease: pathophysiology of osteoblast inhibition," *Blood* (Epub Aug. 17, 2006), 108(13):3992-3996 (2006).
- Gold, M.R., "To make antibodies or not: signaling by the B-cell antigen receptor," *Trends in Pharmacological Sciences*, 23(7):316-324 (Jul. 2002).
- Hantschel et al. "The Btk Tyrosine Kinase is a Major Target of the Bcr-Abl Inhibitor Dasatinib", *PNAS* 104(33):13283-13288 (2007).
- Hiddeman et al. "Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade. Lymphoma Study Group", *Blood* (Epub Aug. 25, 2005), 106(12):3725-3732 (Dec. 2005).
- Horwood et al. "Bruton's Tyrosin Kinase Is Required for Lipopolysaccharide—induced Tumor Necrosis Factor α Production." *J. Exp. Med.*, 197(12):1603-1611 (Jun. 2003).
<http://www.uspto.gov/web/offices/pac/dapp/lpecba.htm#7>, last accessed Feb. 16, 2011.
- Iwaki et al. "Btk Plays a Crucial Role in the Amplification of Fc ϵ R1-mediated Mast Cell Activation by Kit," *J. Biol. Chem.*, 280(48):40261-46270 (Dec. 2, 2005).
- Jefferies et al. "Bruton's Tyrosine Kinase is a Toll/Interleukin-1 Receptor Domain-binding Protein That Participates in Nuclear Factor κ B Activation by Toll-like Receptor 4," *J. Biol. Chem.*, 278:26258-26264 (2003).
- Kawakami et al. "Terreic acid, a quinone epoxide inhibitor of Bruton's tyrosine kinase," *PNAS USA*, 96:2227-2232 (1999).
- Korade-Mirnic et al. "Src kinase-mediated signaling in leukocytes," *J. Leukoc. Bio.*, 68(5):603-613 (Nov. 2000).
- Kuppers, R., "Mechanisms of B-cell lymphoma pathogenesis," *Nature Reviews/Cancer*, 5:251-262 (Apr. 2005).
- Kurosaki, T. "Functional dissection of BCR signaling pathways," *Curr. Op. Imm.* 12:276-281 (2000).
- Liu et al. "Structural Basis for selective inhibition of Src family kinases by PPI." *Chemistry and Biology*, 1999, No. 6, pp. 671-678, in particular table 1, p. 671.
- Luskova, P. and Draber, P., "Modulation of the Fc ϵ Receptor I Signaling by Tyrosin Kinase Inhibitors: Search for Therapeutic Targets
- Mahajan et al. "Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting Bruton's Tyrosine Kinase (BTK), LFM-A13 [α -Cyano- β -Methyl-N-(2,5-Dibromophenyl)Propenamide]," *J. Biol. Chem.*, 274(14):9587-9599 (Apr. 2, 1999).
- Mangla et al. "Pleiotropic consequences of Bruton tyrosin kinase deficiency in myeloid lineages lead to poor inflammatory responses," *Blood*, 104(4):1191-1197 (2004).
- Merged Markush Service Search, Jun. 27, 2005.
- Middendorp et al. "Tumor Suppressor Function of Bruton Tyrosine Kinase is Independent of its catalytic activity", *Blood* 105(1):259-261 (2005).
- Mukoyama et al., "Preparation of imidazol [1,5-a]pyrazine derivatives, pharmaceutical compositions containing them, and their uses for prevention or treatment of protein tyrosine kinase-related diseases," retrieved from STN Database Accession No. 2005:299462 *abstract*.
- Niirio, H. and Clark, E.A., "Regulation of B-Cell Fate by Antigen-Receptor Signals," *Nature Reviews*, 2:945-956 (2002).
- Nisitani et al. "In situ detection of activated Bruton's tyrosine kinase in the Ig signaling complex by phosphopeptide-specific monoclonal antibodies," *PNAS USA*, 96:2221-2226 (1999).
- Oligino, T.J. and Dalrymple, S.A., "Targeting B cells for the treatment of rheumatoid arthritis," *Arthritis Res. Ther.*, 5(Suppl.4):S7-S11 (2002).
- Pan et al. "Discovery of Selective Irreversible Inhibitors for Bruton's Tyrosine Kinase," *ChemMedChem*, 2:58-61 (2007).
- PCT/US06/49626 Search Report dated Apr. 9, 2008.
- PCT/US08/058528 Search Report and Written Opinion dated Sep. 30, 2008.
- PCT/US10/52377 Search Report and Written Opinion mailed Jun. 29, 2011.
- Quek et al. "A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen," *Curr. Biol.*, 8(20):1137-1140 (1998).
- Sada, K. and Yamamura, H., "Protein-Tyrosine Kinases and Adaptor Proteins in Fc ϵ R1-Mediated Signaling in Mast Cells," *Curr. Mol. Med.*, 3(1):85-94 (2003).
- Schaeffer, E.M. and Schwartzberg, P.L., "Tec family kinases in lymphocyte signaling and function," *Curr. Opin. Imm.*, 12:282-288 (2000).
- Science IP CAS Search, Mar. 16, 2006.
- Science IP CAS Search, Sep. 5, 2006.
- Shaffer et al. "Lymphoid malignancies: the dark side of B-cell differentiation," *Nature Rev. Immun.*, 2:920-932 (Dec. 2002).
- Small et al. "Tyrosine Kinase Inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(Phenylamino)pyridinylpyrimidines as Irreversible Inhibitors of the ATP Binding Site of the Epidermal Growth Factor Receptor," *J. Med. Chem.*, 42(10):1803-1815 (1999).
- Smith et al. "The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species," *BioEssays*, 23:436-446 (2001).
- Smolen, J.S. and Steiner, G., "Therapeutic Strategies for Rheumatoid Arthritis," *Nature Reviews*, 2:473-488 (2003).
- Traxler et al., "Use of a Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors: 4-(Phenylamino)pyrazolo[3,4-d]pyrimidines," *J. Med. Chem.*, 40(22):3601-3616 (1997).
- U.S. Appl. No. 12/499,002 Office Action mailed Mar. 3, 2011.
- U.S. Appl. No. 12/499,005 Office Action mailed Feb. 17, 2011.
- U.S. Appl. No. 12/499,008 Office Action mailed Mar. 9, 2011.
- U.S. Appl. No. 12/727,703 Final Office Action mailed Jul. 19, 2011.
- U.S. Appl. No. 12/727,703 Office Action mailed Mar. 3, 2011.
- U.S. Appl. No. 13/011,258 Office Action mailed Nov. 22, 2011.
- Uckun et al. "Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity." *Expert Opinion Ther. Patents* 2010, 20(11):1-14.
- Uckun, F.M., "Bruton's Tyrosine Kinase (BTK) as a Dual-Function

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.